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Leber congenital amaurosis (LCA; OMIM 204000) is 
an inherited ophthalmologic disorder characterized by severe 
visual impairment in early infancy, nystagmus, absent or slug-
gish pupillary responses, high hyperopia, and extinguished 
electroretinogram (ERG) [1,2]. LCA is estimated to affect 1 in 
every 50,000 to 80,000 individuals and accounts for 20% of 
blindness in school-age children [3]. To date, mutations in 24 
genes have been reported to cause LCA, and more causative 
genes continue to be identified (assessed September 2016, 
RetNet) [2,4-7]. These genes encode proteins involved in 
the processes and pathways associated with phototransduc-
tion, retinoid cycle, photoreceptor morphogenesis, guanine 
synthesis, signal transduction, outer segment phagocytosis, 
coenzyme NAD synthesis, and intraphotoreceptor ciliary 
transport.
Genetic testing can definitively diagnose LCA and could 
provide a basis for future gene therapy. Sequencing analyses 
of the known causative genes could identify approximately 
70% of LCA cases [2,8]. However, the genetic heterogeneity 
represented by the large number of associated genes leads to 
difficulties in molecular diagnosis. Moreover, LCA should 
be differentiated from several other systemic disorders, such 
as Joubert syndrome, Zellweger syndrome, neuronal ceroid 
lipofuscinosis, and Senior-Loken syndrome, which exhibit 
similar ocular phenotypes in early infancy [9,10]. Next-
generation sequencing (NGS) technologies have enabled 
the simultaneous detection of multiple candidate genes, and 
several laboratories provide gene panel sequencing or whole-
exome sequencing (WES) [11].
Disease-specific gene panel sequencing can be designed 
to sequence almost all coding regions of the genes that 
cause LCA with high coverage and reliability. However, it 
cannot detect gene mutations for disorders with overlapping 
phenotypes for differential diagnosis or detect mutations in 
other unidentified genes. Such shortcomings can be over-
come by WES; however, using WES in diagnostic testing is 
Molecular Vision 2017; 23:649-659 <http://www.molvis.org/molvis/v23/649>
Received 18 September 2016 | Accepted 18 September 2017 | Published 20 September 2017
© 2017 Molecular Vision
649
Diagnostic application of clinical exome sequencing in Leber 
congenital amaurosis
Jinu Han,1 John Hoon Rim,2 In Sik Hwang,3 Jieun Kim,2 Saeam Shin,2 Seung-Tae Lee,2 Jong Rak Choi2
(The first two authors contributed equally to this work.)
1Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine, Seoul, 
Korea; 2Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea; 3Brain 
Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea
Purpose: Leber congenital amaurosis (LCA) is a hereditary retinal dystrophy with wide genetic heterogeneity. Next-
generation sequencing (NGS) targeting multiple genes can be a good option for the diagnosis of LCA, and we tested a 
clinical exome panel in patients with LCA.
Methods: A total of nine unrelated Korean patients with LCA were sequenced using the Illumina TruSight One panel, 
which targets 4,813 clinically associated genes, followed by confirmation using Sanger sequencing. Patients’ clinical 
information and familial study results were obtained and used for comprehensive interpretation.
Results: In all nine patients, we identified pathogenic variations in LCA-associated genes: NMNAT1 (n=3), GUCY2D 
(n=2), RPGRIP1 (n=2), CRX (n=1), and CEP290 or SPATA7. Six patients had one or two mutations in accordance with 
inheritance patterns, all consistent with clinical phenotypes. Two patients had only one pathogenic mutation in recessive 
genes (NMNAT1 and RPGRIP1), and the clinical features were specific to disorders associated with those genes. Six 
patients were solved for genetic causes, and it remains unclear for three patients with the clinical exome panel. With 
subsequent targeted panel sequencing with 113 genes associated with infantile nystagmus syndrome, a likely pathogenic 
allele in CEP290 was detected in one patient. Interestingly, one pathogenic variant (p.Arg237Cys) in NMNAT1 was 
present in three patients, and it had a high allele frequency (0.24%) in the general Korean population, suggesting that 
NMNAT1 could be a major gene responsible for LCA in Koreans.
Conclusions: We confirmed that a commercial clinical exome panel can be effectively used in the diagnosis of LCA. 
Careful interpretation and clinical correlation could promote the successful implementation of clinical exome panels in 
routine diagnoses of retinal dystrophies, including LCA.
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challenging because of the high burden of interpreting a large 
number of variants of uncertain significance (VUS), issues 
with reporting incidental findings, reduced coverage and reli-
ability in some regions of disease-specific genes, increased 
cost, and prolonged time to obtain final results [12].
Sequencing a few thousand genes with known clinical 
implications, often called clinical exome sequencing, could 
reduce the analytical burden of WES. In this report, we 
evaluate the clinical utility of a commercial clinical exome 
panel in patients with LCA.
METHODS
Patients and families: A total of nine unrelated children 
with LCA were recruited at Severance Hospital from June 
2015 to January 2016. The research protocol was approved 
by the Institutional Review Board of Severance Hospital, 
Yonsei University College of Medicine. This study adhered 
to the tenets of the Declaration of Helsinki. All patients were 
diagnosed with LCA using the following criteria: 1) early 
onset severe visual impairment during the first year of life, 
2) amaurotic pupil accompanied by nystagmus or wandering 
eye movement, 3) extinguished or severely reduced ERG, and 
4) exclusion of other systemic diseases [1]. ERG examina-
tion was performed with an oral sedative, chloral hydrate, 
if patients were uncooperative. ERG protocols adhered to 
International Society for Clinical Electrophysiology of Vision 
standards [13], with some modifications for young infants. 
All patients were offspring of asymptomatic Korean parents, 
and familial genetic testing of the parents was performed in 
seven families.
Library construction and targeted sequencing: Brief ly, 
peripheral blood was collected from basilic or cephalic vein 
in antecubital fossa, with the use of extension tube if needed. 
Whole blood was stored at room temperature for less than 2 
days before it was proceeded to DNA extraction. Genomic 
DNA was extracted from leukocytes of whole blood samples 
using the QIAamp Blood DNA mini kit (Qiagen, Venlo, the 
Netherlands) according to the manufacturer’s instructions 
which used spin-column procedure with automation on the 
QIAcube instrument (Qiagen). Intact DNA was quantified 
and adjusted to a concentration of 5 ng/μl using a Qubit 2.0 
fluorometer (Invitrogen, Waltham, MA) and the Qubit dsDNA 
HS assay kit (Invitrogen). Targeted NGS was performed on 
the DNA using the Illumina TruSight One sequencing panel 
on the MiSeq platform (Illumina, San Diego, CA). Briefly, 
precapture libraries were constructed according to the 
manufacturer’s sample preparation protocol. Each patient’s 
genomic DNA was fragmented with a median size of 300 bp. 
The DNA fragments were end-repaired, phosphorylated, and 
adenylated on the 3′ ends. The index adaptors were ligated 
to the repaired ends, DNA fragments were amplified, and 
fragments of 200 to 500 bp were isolated. Pooled libraries 
were sequenced on a MiSeq sequencer (Illumina) using the 
MiSeq Reagent kit v2 (300 cycles).
Gene targets and NGS data analysis: The TruSight One 
sequencing panel provides targeted sequencing for 4,813 
genes associated with known clinical phenotypes and 
includes 22 causative genes for LCA (AIPL1 Gene ID 23746, 
OMIM 604392; CABP4, Gene ID 64802,OMIM 608700; 
CEP290 Gene ID 80184, OMIM 610142; CRB1 Gene ID 
23418, OMIM 604210; CRX Gene ID 1406, OMIM 602225; 
GDF6 Gene ID 392255, OMIM 601147; GUCY2D Gene ID 
3000, OMIM 600179; IFT140 Gene ID 9742, OMIM 614620; 
IQCB1 Gene ID 9657, OMIM 609237; KCNJ13 Gene ID 3769, 
OMIM 603208; LCA5 Gene ID 167691, OMIM 611408; LRAT 
Gene ID 9227, OMIM 604863; NMNAT1 Gene ID 64802, 
OMIM 608700; PRPH2 Gene ID 5961, OMIM 179605; RD3 
Gene ID 343035, OMIM 180040; RDH12 Gene ID 145226, 
OMIM 608830; RPE65 Gene ID 6121, OMIM 180069; 
RPGRIP1 Gene ID 57096, OMIM 605446; SPATA7 Gene 
ID 55812, OMIM 609868; TULP1 Gene ID 7287, OMIM 
602280; IMPDH1 Gene ID 3614, OMIM 146690, and OTX2 
Gene ID 5015,OMIM 600037) listed in RetNet (last accessed 
September 2016). Two recently discovered genes, DTHD1 
(Gene ID 401124, OMIM 616979) and CLUAP1 (Gene ID 
23059, OMIM 616787) [14,15], are not included in the panel.
Data analysis was performed according to the default 
parameters of the Illumina MiSeq Reporter software. The 
Burrows-Wheeler Aligner (BWA)-MEM algorithm was used 
to read and map the raw sequence data, and the Genome 
Analysis Toolkit (GATK) was used for variant calling. For 
each subject, a vcf file containing variant calls was generated, 
reviewed, and filtered. For every equivocal call in the vcf 
files, a visual inspection of the mapped data was performed 
using the Integrated Genomics Viewer 2.3 software (IGV; 
Broad Institute, Cambridge, MA). For an overview of the 
sequencing coverage, position-wise coverage values were 
calculated from each bam file using the SAMtools software. 
Coverage information was calculated and plotted using the R 
statistics software.
GRCh37 (hg19) was used as the reference sequence for 
mapping and variant calling. Databases used for analysis and 
variant annotation include the Online Mendelian Inheritance 
in Man (OMIM), Human Gene Mutation Database, ClinVar, 
Single Nucleotide Polymorphism database (dbSNP), 1000 
Genome, Exome Aggregation Consortium (ExAC), Exome 
Sequencing Project, and Korean Reference Genome Data-
base, with a minor allele frequency cut-off of 0.5% [16]. The 
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pathogenicity of missense variants was predicted using the 
following in silico prediction algorithms: Sorting Tolerant 
from Intolerant (SIFT), Polymorphism Phenotyping v2 (Poly-
Phen-2), and Mutation Taster.
Validation with Sanger sequencing: All pathogenic varia-
tions or VUS with high priority were validated with Sanger 
sequencing, for the proband and parent samples.
RESULTS
Pathogenic variants identified with NGS analysis using 
TruSight One panel: Quality metrics of the NGS runs 
performed in the nine patients are summarized in Table 1. 
More than 14 million reads were sequenced per sample, and 
approximately 10 million reads were mapped on the target 
regions. Horizontal coverage, the percentage of regions with 
more than 20X coverage, was 92.8%.
In six of the nine patients, pathogenic variants in LCA-
associated genes were detected in accordance with inheri-
tance patterns. In the remaining three patients, only a single 
pathogenic variant for each gene was identified (Table 2). 
P1 had a single pathogenic variant in CRX, and a trio study 
revealed a de novo occurrence. Five patients were compound 
heterozygous for recessive genes: GUCY2D (P2 and P3), 
NMNAT1 (P4 and P5), and RPGRIP1 (P9). For patients with 
available parental samples (P2, P3, P4, and P5), all compound 
heterozygous mutations were confirmed to be inherited each 
from the carrier mother and the carrier father.
In P7, two VUSs in CEP290 and one pathogenic variant 
in SPATA7 were observed. Both CEP290 VUSs were inher-
ited from the father, and one VUS (c.4661_4663delAAG) 
was previously reported as a disease-causing mutation [17], 
but further validation is needed. Because another VUS 1 bp 
upstream of the ATG start site (c.-1G>A) of CEP290 might 
affect gene transcription, the pathogenicity of the VUS could 
not be excluded. Additional sequencing was performed for 
c.2991+1655A>G, a well-known deep intronic mutation in 
CEP290, but the results were negative. The frameshift variant 
in SPATA7 was confirmed to be inherited from the mother. 
Although the same heterozygous variant was reported as 
pathogenic in a Chinese patient with LCA with an additional 
mutation in GUCY2D as digenic manner [18], we concluded 
that this frameshift deletion should be classified as VUS 
based on the results of maternal inheritance and another 
likely pathogenic mutation detected in CEP290 after addi-
tional targeted panel sequencing.
In P6 and P8, only a single mutated allele was found 
in NMNAT1 and RPGRIP1, respectively. Additional copy 
number analyses using the ExomeDepth algorithm and our 
preestablished pipeline failed to find any pathogenic deletion 
or duplication.
Additional targeted panel sequencing with copy number 
variation analysis in three unsolved patients: We performed 
additional targeted panel next-generation sequencing 
analysis with 113 genes responsible for infantile nystagmus 
syndrome in three unsolved patients (Appendix 1). These 113 
genes included two recently discovered genes (CLUAP1 and 
DTHD1) and are listed in a Appendix 1. In P6, additional 
analysis found a nonsense mutation c.3946C>T, p.Gln1316Ter 
in the RP1L1 gene (Gene ID 94137, OMIM 608581). Because 
RP1L1 causes occult macular dystrophy as an autosomal 
dominant inheritance pattern, this novel nonsense variation 
is not related to the patient’s phenotype. In P7, additional 
analysis of targeted NGS revealed a new intronic variant 
c.6012–12T>A CEP290 was found. This mutation was previ-
ously found in Joubert syndrome [19,20] and was classified 
Table 1. QualiTy conTrol meTrics of nexT generaTion seQuencing runs.
Patient Total aligned 
reads
Targeted 
aligned reads
Targeted aligned 
bases (bp)
Mean coverage >=Q30 base 
pair
Median frag-
ment length (bp)
P1 12,248,376 8,305,029 887,342,110 74.3× 91.8% 308
P2 12,514,079 8,734,402 927,395,332 77.6× 92.5% 279
P3 16,477,550 11,991,255 1,235,952,620 103.5× 93.3% 256
P4 14,490,845 10,323,509 1,074,284,233 89.9× 92.9% 267
P5 19,383,130 13,549,987 1,411,822,212 118.2× 88.1% 271
P6 14,609,502 10,076,663 1,039,201,848 87.0× 94.9% 279
P7 13,891,487 9,961,705 1,026,703,521 85.9× 90.0% 259
P8 13,675,583 10,242,904 1,022,195,973 85.6× 90.9% 225
P9 17,416,972 13,005,976 1,312,819,546 109.9× 93.6% 233
Average 14,967,503 10,687,937 1,104,190,822 92.4× 92.0% 264
Abbreviation: bp, base-pair
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as a likely pathogenic mutation based on the result of trans-
detection for recessive disorder in the trio study. In P8, no 
additional variants including copy number variation (CNV) 
were discovered other than the same frameshift mutation in 
RPGRIP1. Because copy number changes might be missed 
by exome-depth algorithms, multiplex ligation-dependent 
probe amplification (MLPA) assay for RPGRIP1 using the 
SALSA MLPA P222 LCA kit (MRC Holland, Amsterdam, 
the Netherlands) was performed. However, the assay also 
failed to discover any deletion or duplication, including the 
exon 17 deletion previously reported in Japanese patients with 
LCA [21].
Genotype-phenotype correlation: Demographic and clinical 
features of the enrolled patients are summarized in Table 3. 
None of the nine patients had syndromic features such as 
hearing loss, renal failure, or gross motor delay. All patients 
were babies around 1 year of age except P9 who was advised 
for genetic testing at the age of 29 years. Considering the 
association between affected genes and fundus findings, the 
patients carrying GUCY2D mutations (P2 and P3) showed 
grossly normal retinal appearances without noticeable 
retinal vessel caliber changes or pigmentary changes. In 
addition, patients carrying NMNAT1 mutations (P4, P5, and 
P6) displayed macular coloboma-like atrophic lesions and 
retinal vessel narrowing that were discovered in early infancy 
(Figure 1). Although we found only a single pathogenic 
variant in NMNAT1 (p.Arg237Cys) in P6, the retinal exami-
nation of that patient showed a typical macular coloboma-like 
lesion in early infancy. None of these patients had overt optic 
atrophy at the time of examination.
No developmental delay or systemic abnormalities were 
found in the patient with suspected CEP290 mutations (P7). 
This 7-month-old female had oculodigital sign and wandering 
eye movement. The retinal examination showed a normal 
optic disc, no pigmentary retinopathy, and only mild vessel 
narrowing.
Interestingly, P9 was initially misdiagnosed with idio-
pathic infantile nystagmus because the initial fundus finding 
was grossly normal in early infancy. The patient underwent 
Anderson-Kestenbaum surgery at the age of 6 years for 
significant left head turn. His best-corrected visual acuity 
remained 20/200 bilaterally. At the age of 29 years, targeted 
NGS revealed a compound heterozygous RPGRIP1 mutation 
in this patient. Dilated fundus examination showed mild 
vessel attenuation and temporal optic atrophy without overt 
retinal pigmentary changes. Optical coherence tomography 
showed a relatively preserved inner segment and outer 
segment line (Figure 2).
The c.709C>T, p.Arg237Cys variant in the NMNAT1 gene 
is known as a pathologic variant. This variant was found in all 
three individuals with macular coloboma-like degeneration, 
including one heterozygous individual (Figure 3). The allele 
frequency is 0.000074 (nine alleles out of 121,284 alleles are 
reported) in the ExAC browser and 0.00031 (two alleles out 
of 6,501 alleles) in the Exome Variant Server. However, the 
c.709C>T allele frequency was 0.0024 in the Korean Refer-
ence Genome Database (KRGDB), which consists of the 
whole exome sequencing results for 622 Korean individuals, 
suggesting that this mutation is relatively common in the 
Korean population.
DISCUSSION
Several custom NGS panels [22,23] and commercial panels 
[24] have been reported to show high diagnostic utility in 
patients with LCA. We evaluated a commercial clinical 
exome kit that encompasses 4,813 genes associated with 
known clinical phenotypes, including 22 genes associated 
with LCA. The panel also includes genes for other retinal 
disorders and can help make a differential diagnosis. For 
example, differentiation of LCA from achromatopsia or 
syndromic retinal disorders is practically impossible, 
especially in young infants. These disease entities not only 
present similar phenotypes in early infancy but also geneti-
cally overlap each other (e.g., mutations in CEP290 cause 
either Joubert syndrome or LCA). Another strength of using 
commercial kits is the feasibility of standardization and inter-
laboratory harmonization. However, the list of disease-related 
genes is rapidly expanding [15], which suggests that using a 
fixed set could miss candidate genes. Therefore, new genes 
like CLUAP1 can be missed with a clinical exome kit that 
targets already known genes that cause LCA. Another draw-
back is that targeting too many genes could lead to a reduced 
average depth of coverage and more regions with low depth. 
In a missense RPGRIP1 variant (P9), the depth of coverage 
was 13, and further confirmation with Sanger sequencing was 
needed.
LCA can be diagnosed at an early age with careful clin-
ical examination and ERG testing. Considering the progres-
sive nature of retinal degeneration in LCA, early molecular 
diagnosis could open up an opportunity to initiate a gene 
therapy trial [25]. Although still in clinical trials, recent 
gene therapy studies have shown that great improvements in 
visual acuity can be achieved in young patients with better 
baseline visual acuity [26]. Initial phase 1 and 2 trials of a 
gene therapy for RPE65 have been accomplished [27], and 
those for GUCY2D and gene editing for CEP290 are under 
investigation [28,29].
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Genotype–phenotype correlation is important in 
narrowing down causative genes, particularly in genetically 
heterogeneous disorders. The present study showed that all 
three patients with coloboma-like macular atrophic lesions 
had NMNAT1 mutations, whereas those with grossly normal 
retinal appearances had mutations in GUCY2D, CRX, and 
CEP290, consistent with previous reports [30,31]. The other 
types of LCA with macular atrophic lesions present in infancy 
or later in life have been reported to occur in individuals 
carrying mutations in AIPL1, CRB1, RDH12, RPGRIP1, 
TULP1, and RPE65 [32-34]. Those other types show progres-
sive macular degeneration in the natural course, whereas 
macular coloboma-like degeneration in early infancy could 
be specific to mutations in NMNAT1. Therefore, single-gene 
sequencing of NMNAT1 could be a cost-effective strategy in 
Figure 1. Color photographs of the 
retinas of six patients with LCA. 
A, B: Two 6-month-old babies (P2 
and P3) with compound heterozy-
gous mutations in GUCY2D (p.[
Phe993LeufsTer13]+[Gly1013G
lu] and p.[His664Pro]+[Phe883L
eufsTer13], respectively) have no 
definite abnormal finding (OD) in 
the retina. C: A 7-month-old baby 
(P5) with compound heterozygous 
missense mutations in NMNAT1 
(p.[Arg66Trp]+[Arg237Cys]) has 
marked chorioretinal atrophic 
changes in the macula with vessel 
narrowing and mild pigmentary 
changes (OD). D: A 1-year-old 
baby (P6) with only one patho-
genic mutat ion in NMNAT1 
( p.[A rg 237Cys]+[?])  shows 
nystagmus, hyperopia, and a 
characteristic macular coloboma-like lesion (OS). E: An 8-month-old baby (P8) presented with poor eye contact, extinguished electro-
retinogram, +6.00 diopters hyperopia, slight optic disc pallor, and mild vessel narrowing (OD). We identified one frameshift mutation 
(p.Arg1189GlyfsTer7) in RPGRIP1. F: A 29-year-old male (P9) presented with nystagmus developed at the age of 6 years, 20/200 acuity, 
optic atrophy, and mild vessel attenuation (OD). Compound heterozygous mutations were identified in RPGRIP1 (p.[Tyr693Ter]+[c.2212_
2215+21del]).
Figure 2. Fundus photographs of a 29-year-old male with mutations in RPGRIP1 who was initially misdiagnosed with idiopathic infantile 
nystagmus. He had sustained left head turn posture with left beating jerk nystagmus. Anderson-Kestenbaum surgery was performed at the 
age of 6 years. At the age of 29 years, his best visual acuity was 20/200 bilaterally. A, B: Fundus photography shows mild optic atrophy with 
retinal vessel attenuations. C, D: Spectral domain optical coherence tomography shows thinning of the inner segment and outer segment line.
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patients with macular coloboma-like degeneration in early 
infancy, especially when NGS testing is unavailable.
One patient with mutations in RPGRIP1 (P9) was 
initially misdiagnosed with an idiopathic form of infantile 
nystagmus, but the diagnosis changed because of the NGS 
results. Most patients with mutations in RPGRIP1 have 
a grossly normal fundus in early infancy [35]. Khan et al. 
reported a 6-year-old girl with a mutation in RPGRIP1 whose 
nystagmus abated when she adapted a moderate right face 
turn [35]. Thus, careful clinical examination, including of the 
peripheral retina, is essential in the diagnosis of LCA, and 
meticulous ERG testing should be conducted in patients who 
exhibit poor visual acuity.
One patient (P7) had two heterozygous VUSs in CEP290, 
of paternal origin, and one heterozygous pathogenic variant 
in SPATA7 of maternal origin. It is possible that mutations 
in those genes work together as “digenic inheritance” [36]. 
However, additional targeted panel sequencing revealed 
another intronic variant in CEP290 that could be classified 
as likely pathogenic and was confirmed to be inherited from 
the mother. Although LCA has been known to be inherited 
as digenic pattern in some reports [36-38], it is important to 
be cautious about the possibilities of a digenic inheritance 
because genetic testing might miss mutations in the affected 
gene.
Several genetic studies of patients with LCA have been 
performed in different ethnic groups [39,40]. Seong et al. 
[22,41,42] performed consecutive genetic studies on a few 
genes in Korean patients with LCA but failed to find any 
founder mutation. Through comprehensive testing on several 
genes, we found three common alleles associated with LCA: 
GUCY2D c.2649delT, NMNAT1 c.196C>T, and NMNAT1 
c.709C>T. NMNAT1 was only recently identified as a caus-
ative gene for LCA. The minor allele frequency of NMNAT1 
c.709C>T (p.Arg237Cys; rs375110174) is estimated to be as 
high as 0.24% (Korean Reference Genome DB). Therefore, 
mutations in NMNAT1 and GUCY2D might be major genes 
responsible for LCA in Koreans, which contrasts with the 
high frequency of mutations in CEP290 in Caucasian popu-
lations [2]. Additionally, one frameshift mutation found in 
RPGRIP1 in P8 has also been reported in another Korean 
patient [41].
In conclusion, the present study supports the utility of 
clinical exome sequencing in LCA diagnosis and differential 
diagnosis from other syndromic diseases with overlapping 
ocular phenotypes. Understanding the technology, applying 
careful interpretation, supplementing with other testing, 
and correlating with clinical phenotypes could lead to the 
successful implementation of clinical exome sequencing in 
the routine diagnosis of inherited retinal disorders, such as 
LCA.
APPENDIX 1. TARGET GENES WERE LISTED.
To access the data, click or select the words “Appendix 1.” 
Genes included in infantile nystagmus syndrome target 
enrichment. Listed are the genes included in the custom 
designed target enrichment along with the disease or pheno-
type associated with the gene according to Online Medelian 
Inheritance in Man (OMIM), OMIM phenotype identifica-
tion number, and OMIM or Gene Cards gene identification 
number. Genes are named according HUGO Gene Nomen-
clature Committee (HUGO, http://www.genenames.org/) 
approved nomenclature.
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